Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 3,201–3,300 of 3,636
Nanoparticles for the Treatment of Ischemic Heart Diseases
Mohamed, N. A., Benslimane, F. M., & Zakaria, Z. Z. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837671113-00047
Statins in the practice of an internal medicine specialist: A review
Susekov, A. V. (2024) · Consilium Medicum · doi:10.26442/20751753.2024.10.202995
Ren, J., Zhang, H., Shao, X., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5028060
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.004 · Cited by 2
El control estricto del colesterol aterogénico en la prevención de las enfermedades cardiovasculares
Guijarro, C. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.10.004 · Cited by 2
CDA-AMC (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.1040
(2000) · Time to knit · doi:10.1016/s2211-0364(20)90382-5
(2000) · Time to knit · doi:10.1016/j.ccol.2023.02.006
(2000) · Time to knit · doi:10.1016/s1155-1941(23)46691-7
(2000) · Time to knit · doi:10.1016/s1155-1941(19)84494-3
New Cardiovascular Medications: Surveying Adoption Trends Among CardiologistsPreprint
Varjabedian, L., Mohammadi, A., Mohammadi, A., et al. (2025) · medRxiv · doi:10.1101/2025.01.14.25320511
(2000) · Time to knit · doi:10.1016/s1877-7848(21)45592-9
(2000) · Time to knit · doi:10.1016/s2211-0364(23)46611-3
(2000) · Time to knit · doi:10.1016/s1634-6939(20)88012-0
Oyenubi, O., & Jia, X. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07671-8
Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial
Packard, C. J., Borén, J., & Chapman, M. J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.124
Ross, L. J. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2024.11.011
Parhofer, K. G., Bramlage, P., Gries, C., Harder, C., Look, C., Paar, W. D., & Rauch‐Kröhnert, U. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00471-w
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
The Impact of Lipoprotein (A) on Autoinflammation and its Significance in Cardiogeriatrics
Korotkova, E. V., Zavyalov, A. V., & Kovalenko, A. Y. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2024-335-341
Strict control of atherogenic cholesterol and cardiovascular disease prevention
Guijarro, C. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100744
Risk Signal Mining and Analysis of PCSK9 Inhibitors Based on FAERS DatabasePreprint
Peng, L., Xie, M., Feng, B., Pu, X., Zhang, Z., Fan, C. H., Li, C., & Wang, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116760
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100739 · Cited by 1
Chung, J. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2024.0434
Shehab, H. F., Rajan, R., Al‐Jarallah, M., Dashti, R., Al-Sarraf, A. J., Alsaber, A., Tse, G., AlObaid, L., & Lansberg, P. J. (2025) · Annals of Clinical Cardiology · doi:10.4103/accj.accj_28_24
Bénétos, A., & Bauduceau, B. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.006 · Cited by 1
Jiang, F., Yin, S., & Zhang, X. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1548147
“Despite signi fi cant advancements in surgical and pharmacological treatments, survival rates have improved but the post-myocardial infarction landscape is still fraught with complications and a marked decline in quality of life (Schwartz et al., 2018).”
Research Progress of Cardiovascular Protection Mechanism of PCSK9 Inhibitors
李, 慧. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153854
PCSK9 Targeted Therapy to Lower Cholesterol and Reduce Cardiovascular Events
Abramson, B. L., & Nelson, S. M. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.114
Peasah, S. K., Lee, T., Do, D., Huang, Y., Inneh, A., Patel, U. B., Aiyer, A., & Good, C. B. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.4.377
Update kardiovaskuläre Prävention 2025
Wienbergen, H., Hanses, U., Kerniss, H., & Hambrecht, R. (2025) · Herz · doi:10.1007/s00059-025-05305-1
“…in Subjects with Elevated Risk)- bzw. in der ODYSSEY(Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Aliro-cumab)-Outcomes-Studie gezeigt, dass durch die Therapie eine signifikante Reduktion unerwünschter Ereignisse erreicht werden kann [35, 36].”
Managing diabetes and cardiovascular disease
Morris, D. (2025) · Independent Nurse · doi:10.12968/indn.2025.4.18
Two years experience of using alirocumab in patients with dyslipidemia
Babushkina, G. V., Gubaeva, A., Shestova, K., et al. (2025) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio202518021216
Chen, L., Li, M., Deng, Y., Chen, Z., Huang, R., Yang, X., & Huang, Z. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70072
“7,8 However, real-world evidence with its use in Chinese ACS patients is not sufficient.”
Lipid lowering with inclisiran: a single-center experience from Slovakia
Tóth, Š., Vachalcová, M., Jarolimkova, A., Sevcik, M., & Porubän, T. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.017
Fan, T., Yan, Y., Wang, J., Li, J., Xu, G., Lü, Q., & Chen, H. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2025.04.005
The Life Cycle of Drug Development
Chirmule, N. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-81787-8_1 · Cited by 1
Familial Hypercholesterolemia in Women: Assessment, Diagnosis, and Treatment
Demeter, S. H., & Lew, K. (2025) · Clinical Journal for Nurse Practitioners in Women s Health · doi:10.1891/cjnpwh-2505
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials
Hogan, S. E., Canonico, M. E., King, R. W., Wang, C. C. L., Nehler, M. R., Parr, J., Rogers, R. K., Lu, W., Albanese, J., Barnathan, E. S., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101763
Sigal, A., Antoniolli, M., Santi, P. L., Aquino, N., Lerech, E., & Botto, F. O. (2021) · Revista Argentina de Cardiología · doi:10.7775/rac.v89.i5.20409 · Cited by 2
“The ODDYSEY Outcomes study demonstrated a similar risk reduction with the use of alirocumab on a composite of cardiovascular death, non-fatal infarction, stroke, or unstable angina in patients with AMI or recent unstable angina, (16).”
Potential bias in observational PCSK9 inhibitor study
Blais, J. E., & Wong, A. Y. S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf041
Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5266617
Garjón, J. (2025) · Boletín de información farmacoterapéutica de Navarra · doi:10.54095/bitn20253202
MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
Lee, C. J., Go, M., Jeon, S., Lee, S.-H., Min, D., Park, S. H., Lee, S., & Park, S. W. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102589
Prévention secondaire chez le coronarien
Sorbets, E. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)48213-1
Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal
van Bruggen, F. H., & Luijendijk, H. J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1564432
Xu, L., Lei, M., Li, L., Li, Y., Gu, C., & Zheng, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1555508 · Cited by 1
“The ODYSSEY OUTCOMES trial showed that alirocumab signi fi cantly reduced the risk of cardiovascular outcomes in participants with a baseline LDL cholesterol level of ≥ 100 mg/dL (Schwartz et al., 2018).”
InfluentialErmolaeva, A. D., Ermolaeva, T. N., & Александрович, К. К. (2025) · Kardiologiia · doi:10.18087/cardio.2025.6.n2949
Impact of Preoperative LDL Level on Lower Extremity Revascularization Outcomes
Carter, W. J., Alappan, U. D., Chetty, A. K., Wells, N., Alameddine, D., Slade, M. D., Possick, S. E., & Chaar, C. I. O. (2025) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2025.07.016
Advanced Biologics and Smart Delivery Systems for Cardiovascular Diseases: A Comprehensive Review
Ghasura, P., Sajnani, B. M., Tanveer, M. A., Barath Raj, R., & Sharma, A. (2025) · International Journal of Scientific Research in Science and Technology · doi:10.32628/ijsrst251268
PCSK9 INHIBITORIŲ EFEKTYVUMAS GERINANT PACIENTŲ LIPIDŲ PROFILĮ PO MIOKARDO INFARKTO
Linkevičiūtė, G., & Černel, V. (2025) · Health Sciences · doi:10.35988/sm-hs.2025.215
Treatment of dyslipidemia: PCSK-9 in focus
Lukač, S. S., Popović, L., Rasulić, I., Petakov, A., Bogdanović, J. M., Mitrović, M., Krstic, M., & Lalic, K. S. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-55356
PCSK9 reloaded: sirtuin-1 as a post-translational checkpoint for LDL-C control
Pirillo, A., & Catapano, A. L. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf126
Nicholls, S. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001002 · Cited by 2
Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251361059
Pro-Inflammatory and Lipid Metabolism Dysregulating Effects of ANGPTL3 in THP-1 Macrophages
Milani, I., Rossi, I., Marodin, G., Lupo, M. G., Adorni, M. P., Zimetti, F., & Ferri, N. (2025) · Lipidology · doi:10.3390/lipidology2030014
“…effective therapies are represented by the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), including the monoclonal antibodies evolocumab [3] and alirocumab [4] and the novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) inclisiran [5].”
Pan, Y., Tsai, Y., Weng, H., et al. (2025) · medRxiv · doi:10.1101/2025.08.04.25332997
Lim, Y., Jang, S., Lee, E., & Park, M.-H. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02677-5
Арманович, А. А., Kaktursky, L. V., Urazova, O. I., Трофименко, А. И., Sukiasyan, L. M., Коган, Е. А., Демура, Т. А., & Вачиковна, П. Н. (2025) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-2-124-140 · Cited by 1
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
Searle, J., & Bessada, Y. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70107
Kakizaki, R., Ueki, Y., Koskinas, K. C., et al. (2025) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-025-03472-0
“Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) added to statins potently reduce LDL-C and thereby result in signi�cant plaque regression and cardiovascular bene�ts compared with statin therapy alone [13, 14].”
Cardiovascular Outcome Trials in Type 1 Diabetes: We Are Not There Yet
Hirsch, I. B., & Eckel, R. H. (2025) · Diabetes Care · doi:10.2337/dci25-0062
Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence
Shi, X., Wang, S., Yang, Y., Xia, X., Fan, J., Wang, J., Wang, N., & Jia, X. (2025) · Pharmacy · doi:10.3390/pharmacy13050125
Tejada-González, C., Bonilla-Jiménez, V., Ruiz-Saavedra, A., Serpa-Morán, J. A., Leandro-Barros, A., & García‐Lledó, A. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.08.011
Role of stroke volume in patients presenting with uncomplicated anterior STEMI
Omari, M., James, N., Brown, A. J., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003429
Popiołek-Kalisz, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.arteri.2025.500846 · Cited by 1
3) SiRNA Drug Inclisiran for Lowering Serum LDL-cholesterol Levels
Yamashita, S. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1572
Wu, S., Hsu, L., Yeh, K.-H., & Ko, Y. (2025) · Genes · doi:10.3390/genes16091113 · Cited by 1
“Recent clinical outcome trials have demonstrated that the PCSK9 inhibitor therapy significantly reduce the risk of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease [46,47].”
Strimaitis, B. J., Francis, L. P., & O'Sullivan, E. D. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101125
Coronary Plaque Regression: A Review of the Role of Lipid-Lowering Agents
Adhikari, A., Wutawunashe, C. V., Kim, M., & Kodra, A. (2025) · International Journal of Angiology · doi:10.1055/a-2692-1482
Management kardiovaskulärer Risikofaktoren
Weiss, N., & Dörr, G. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60880-7_16
Prevención secundaria en el paciente coronario
Sorbets, E. (2025) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(25)51065-6
Heneha, M. B., Marushko, Y. Y., & Mankovskyi, G. B. (2025) · Ukrainian journal of cardiovascular surgery · doi:10.63181/ujcvs.2025.33(3).25-30
“Підвищений рівень Lp(a) асоціюється зі швидшим прогресуванням частотою рестенозів після перкутанних коро-нарних втручань [25].”
InfluentialWhere is the treatment of atherosclerosis heading?
Mayer, O. (2025) · Medicína pro praxi · doi:10.36290/med.2025.050
Kounatidis, D. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00287-9
Hoang, V. B., Koltsov, A. V., Kachnov, V. A., Makhova, O. A., Sarana, А. М., & Tyrenko, V. V. (2025) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20252809178
Dziewierz, A., Bobrowska, B., Streb, W., Pelliccia, F., Bartuś, S., & Rajtar-Salwa, R. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2570839 · Cited by 1
“The most common adverse events are mild and transient injection-site reactions (e.g. erythema, pain, bruising) [68,70].”
Störungen von Ernährung und Stoffwechsel
Parhofer, K. G., & Hauner, H. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21184-3.00008-9
Quarante ans d’avancées en cardiologie
Tedgui, A., & Taleb, S. (2025) · médecine/sciences · doi:10.1051/medsci/2025130
Follicular Helper T Cells: Potential Interventional Targets in Atherosclerosis
Chen, Y., Wang, W., Xia, X., Xu, X., & Wang, S. (2025) · Journal of Immunology Research · doi:10.1155/jimr/9247816
PCSK9 in critical illness – It’s not all about lipids
Crossley, E., Silversides, J. A., O’Kane, C. M., & Hamilton, P. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251395579
“38,39,41,42 The morbidity and mortality bene fi ts of these mAbs are also widely reported in the literature.”
Tratamiento de la angina estable
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Álvarez, D. I., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.003
Protocolo de prevención primaria y secundaria de la cardiopatía isquémica
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Iglesias-Álvarez, D., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.008
Truong, T., Anh, T. H., Hoang, S. V., Nguyen, N. Q., Hoa, T., Nguyen, D. C., Nguyen, H. D., Dang, H. N. N., Luong, T. V., Do, D. L., et al. (2025) · Health Science Reports · doi:10.1002/hsr2.71436
“C, can significantly lower cardiovascular risk and provide substantial benefits for patients with ASCVD [4, 5].”
Beyond Statins—Expanding the Arsenal of Lipid-Lowering Therapies
O’Donoghue, M. L., & Marston, N. (2025) · JAMA · doi:10.1001/jama.2025.20965
Zhang, Y., Liu, X., Song, K., et al. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.11.004
Yeh, J., Chen, H., Lan, X., Huang, C., Chen, Y.-L., Wang, Y.-T., Shao, P., Ko, S., Guo, J., & Yip, H. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003728 · Cited by 1
谭, 静. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113213
Yang, W., Lee, Y., Kim, E., Cho, H., Yu, S., Kim, J., Shin, J. W., Lee, S. J., Kim, B. J., Hong, J. M., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02781-6 · Cited by 1
“Lipid-lowering therapy is a cornerstone of mitigating recurrent CVD risk, with accumulating evidence supporting progressively lower low-density lipoprotein cholesterol (LDL-C) targets [1–7], summarized by the widely recognized notion that “the lower, the better”.”
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Cell modeling and rescue of a novel noncoding genetic cause of glycogen storage disease IX
Iyengar, A. K., Zou, X., Dai, J., Francis, R. A., Safi, A., Patterson, K., Koch, R. L., Clarke, S., Beaman, M. M., Mohan, S., et al. (2025) · Genetics in Medicine Open · doi:10.1016/j.gimo.2025.103474
Dermiki‐Gkana, F., Gravel, C. A., Kontogiorgis, C. A., & Douros, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-24945-1
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Von Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
Document de Consensus Sur la Prise en Charge du Cholestérol LDL
Mach, F., Gallino, A., Haegeli, L., Kobza, R., Koskinas, K. C., Miserez, A. R., Nanchen, D., Pedrazzini, G. B., Räber, L., Sudano, I., et al. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02110
Prevenzione secondaria nel paziente affetto da coronaropatia
Sorbets, E. (2025) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(25)51186-5
Catapano, A. L., Maggioni, A. P., Rossi, F., Consolo, E., Notarianni, L., & Agnelli, G. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200549
Kumar, P., Prajapathi, S., Singh, A., Pradhan, A. K., Shukla, A., Bhandari, M., Sharma, A., Vishwakarma, P., Chaudhary, G., Chandra, S., et al. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200558 · Cited by 3
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

